Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period of 627.11 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod · last filed 2021-02-25
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2018-12-31 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2018-09-30 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2018-06-30 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2018-03-31 was 627.11K shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for fiscal 2018 was 627.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 12 month |
|---|---|---|---|---|
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 0.00 shares derived: sum of 2 quarters · filed 2021-02-25 | 0.00 shares derived: sum of 3 quarters · filed 2021-02-25 | 627.11K shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2018-11-13 | 627.11K shares 10-Q · filed 2018-11-13 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | 627.11K shares 10-Q · filed 2018-08-10 | ||
| 2018-03-31 | 627.11K shares 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |